Cibus (CBUS) Cash & Equivalents (2016 - 2026)
Cibus (CBUS) posted Cash & Equivalents of $9.9 million for Q4 2025, down 58.48% sequentially from $23.9 million in Q3 2025, and down 31.25% YoY from $14.4 million in Q4 2024.
Cibus (CBUS) Cash & Equivalents (2016 - 2026) Analysis & Trends
Cibus has reported Cash & Equivalents for 10 years, with the latest figure at $9.9 million in Q4 2025.
- Quarterly Cash & Equivalents fell 31.25% year-over-year to $9.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.9 million (down 31.25% YoY) and the FY2025 annual result came in at $9.9 million, down 31.25% from the prior year.
- Cash & Equivalents retreated to $9.9 million in Q4 2025 per CBUS's latest filing, from $23.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $50.9 million in Q2 2023 and troughed at $2.1 million in Q1 2023.
- A 5-year average of $20.5 million and a median of $17.4 million in 2021 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 88.12% in 2023, then surged 1093.14% in 2024.
- Over 5 years, Cash & Equivalents stood at $13.8 million in 2021, then tumbled by 75.21% to $3.4 million in 2022, then surged by 854.16% to $32.7 million in 2023, then slumped by 55.86% to $14.4 million in 2024, then tumbled by 31.25% to $9.9 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $9.9 million, $23.9 million, and $36.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | 20.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.43 Mn |
| Dec 31, 2025 | 9.92 Mn |
| Sep 30, 2025 | 23.90 Mn |
| Jun 30, 2025 | 36.50 Mn |
| Mar 31, 2025 | 23.59 Mn |
| Dec 31, 2024 | 14.43 Mn |
| Sep 30, 2024 | 28.81 Mn |
| Jun 30, 2024 | 30.00 Mn |
| Mar 31, 2024 | 24.51 Mn |
| Dec 31, 2023 | 32.70 Mn |
| Sep 30, 2023 | 31.88 Mn |
| Jun 30, 2023 | 50.90 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 7.03 Mn |
| Jun 30, 2022 | 11.32 Mn |
| Mar 31, 2022 | 17.29 Mn |
| Dec 31, 2021 | 13.82 Mn |
| Sep 30, 2021 | 13.92 Mn |
| Jun 30, 2021 | 17.49 Mn |